



November 8, 2017

Genocea to Present at Stifel 2017 Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced that Chip Clark, president and chief executive officer, will present a company overview at the Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017 at 8:45 a.m. ET in New York City.

A live webcast of the presentations can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at <http://ir.genocea.com>. A replay of the webcasts will be archived for 30 days following the presentation.

About Genocea Biosciences, Inc.

Genocea is harnessing the power of T cell immunity to develop potentially life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. Genocea is exploring strategic alternatives for GEN-003, its Phase 3-ready immunotherapy candidate for the treatment of genital herpes. For more information, please visit www.genocea.com.

For media:

Jennifer LaVin

O: 617-715-6687

jennifer.lavin@genocea.com

For investors:

Jonathan Poole

O: 617-876-8191

jonathan.poole@genocea.com

Source: Genocea Biosciences, Inc.

News Provided by Acquire Media